THE NEXT GENERATION OF IMMUNOTHERAPY

Immunovative Therapies, Ltd. is a clinical stage Israeli biopharmaceutical company specializing in the translation of proven immune mechanisms into immunotherapy products and protocols for treatment of cancer and infectious diseases. Our patented “Mirror EffectTM” technology provides an immunological platform for the development of drugs that elicit the same powerful anti-tumor and anti-HIV effects of bone marrow/stem cell transplant procedures while eliminating the devastating side effects of the procedure and the need for a tissue matched donor. We have two products in clinical development: AlloStim®, a bioengineered living cell allograft; and Chaperone-Rich Cell Lysate (CRCL), a patient-specific heat shock protein vaccine. AlloStim combines with a tumor cryoablation (killing by freezing) method to create an in-situ cancer vaccine called CryoVaxTM and combines with CRCL to create a personalized cancer vaccine called AlloVaxTM.

Button

Immunovative is the Future of Immunotherapy

Immunovative is the Future of Immunotherapy

CONTROLLING IMMUNE NETWORKS

CONTROLLING IMMUNE NETWORKS

SPECIALITY INFORMATION

patients

Treatment strategy designed to use the power of the human immune system to kill tumors and prevent their recurrence.
No requirement for a matched donor or chemotherapy/radiation conditioning prior to treatment.
Innovative technology – proven and non-toxic.
read more

Healthcare professionals

Therapeutic anti-tumor vaccine developed from core break-through technology called the "Mirror Effect™“ which opens a pathway to treating patients with metastatic cancer that have failed all available therapy options.
Elicits a GVT-like mechanism without the GVHD toxicity.
read more

Investors

Privately-held Israeli biopharmaceutical company spin out from Hadassah-Hebrew University Medical Center with headquarters in Jerusalem.

Over 200 individual private shareholders and grant support from the Israel Office of the Chief Scientist.
read more